Other languages Cybin Inc.

Equities

CYBN

CA23256X1006

Market Closed - Nyse Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
0.35 ^USD	+0.11%		-1.71%	-14.63%

May. 06	Cybin Provides Corporate Provides Update Highlighting Recent Clinical Accomplishments and Key Upcoming Catalysts Across Its Development Pipeline	CI
Apr. 17	Numinus Wellness Brief: Says Cedar Clinical Research Selected as clinical research site for Cybin's Phase 3 Study of CYB003	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cybin to Participate at the Pathways to Access Summit and the Interdisciplinary Conference on Psychedelic Research 2024	May. 29
Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase	May. 14
Cybin Provides Corporate Update and Highlights Upcoming Clinical Milestones	May. 07
Cybin Provides Corporate Update and Highlights Upcoming Clinical Milestones	May. 06
Cybin Provides Corporate Provides Update Highlighting Recent Clinical Accomplishments and Key Upcoming Catalysts Across Its Development Pipeline	May. 06
Cybin to Participate at the 27th Annual Milken Institute Global Conference	Apr. 25
Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry	Apr. 18
Numinus Wellness Brief: Says Cedar Clinical Research Selected as clinical research site for Cybin's Phase 3 Study of CYB003	Apr. 17
Cybin Secures US Patent for CYB003 Program in Major Depressive Disorder Treatment	Apr. 16
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder	Apr. 16
Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference	Apr. 10
Cybin : MATERIAL CHANGE REPORT - Form 6-K	Mar. 22
Cybin : AGENCY AGREEMENT - Form 6-K	Mar. 21
Cybin Inc. announced that it has received $150 million in funding from a group of investors	Mar. 18
Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas	Mar. 18
Sector Update: Health Care Stocks Softer Friday Afternoon	Mar. 15
Cybin Starts Phase 2 Proof-of-Concept Study in Generalized Anxiety Disorder	Mar. 15
Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder	Mar. 15
Cybin Inc. Initiates Phase 2 Proof-Of-Concept Study of Cyb004 in Generalized Anxiety Disorder	Mar. 15
Discovering Promising Tech Stocks: QBTS, GEVI, CYBN, RSCI, CLRO	Mar. 15

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Cybin Inc.

Equities

CYBN

CA23256X1006

Other languages

Filters